Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Intradigm Selects Agilent as Manufacturing Partner for RNAi Oncology Therapeutic

  • Intradigm chose Agilent Technologies to manufacture the active siRNA component of its RNAi therapeutic. In addition, Intradigm selected ICS-283 as its lead RNAi product candidate.

    Under terms of the agreement, Agilent will support the initiation of clinical development for ICS-283. Intradigm expects to initiate trials in 2008.

    ICS-283 is the only systemic RNAi therapeutic in preclinical development against a clinically validated oncology target (vascular endothelial growth factor or VEGF), according to Intradigm. It is a nanoparticle-based compound comprised of multiple siRNAs that target both VEGF and its receptor.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »